Analyst Consensus ?
ConsensusHold42 ratings
Bullish1740.5%
Neutral2252.4%
Bearish37.1%
Zimmer Biomet Holdings, Inc. · ZBH · FY2025 Q3 · Calendar Q4 2025
Zimmer Biomet maintains EPS outlook as new products drive Q3 growth
The quarter supports a constructive but qualified view: product innovation, robotics adoption and procedure-volume tailwinds can support growth, but the durability of demand and execution against regional, restorative-therapy and revision-market headwinds remain important tests.
Reported Before market openNYSEHealthcare
$17.08B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.90
Consensus $1.87
EPS surprise
+1.6%
Reported versus consensus
Reported revenue
$2.00B
Consensus $2.01B
Revenue surprise
-0.5%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-15.1%
Event window
SPY move
+0.3%
Same window
Abnormal move
-15.5%
Stock minus SPY
Volume
6.3×
Versus trailing sessions
Subsequent drift
+6.4%
Up to 20 sessions
ZBHSPY benchmark
Ask FN2 about ZBH FY2025 Q3
Transcript, numbers and history already loaded
Why did ZBH fall 15.1% after beating EPS estimates in FY2025 Q3?What changed in ZBH's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ZBH after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, Q3 showed stronger reported organic growth at 5%, but management maintained rather than raised guidance. The analysis also highlighted a modest U.S. revision-market slowdown and approximately 120 basis points of pressure from Eastern Europe, Latin America and restorative therapies.
Guidance delta
Management maintained FY2025 adjusted EPS guidance of $8.10-$8.30 and narrowed organic revenue growth guidance to 3.5%-4%.
Key takeaways
- Q3 organic sales grew 5%, led by U.S. knee products and robotics.
- The innovation pipeline includes iodine-treated implants, ROSA enhancements, Monogram robotics and Paragon 28 products.
- Restorative-therapy weakness, emerging-market softness and a slower revision market remained headwinds.
Management priorities
- Execute the new product pipeline across knees, hips, robotics and foot and ankle.
- Advance Monogram's semi-autonomous and fully autonomous robot platforms.
- Integrate Monogram and Paragon 28 while maintaining cash generation and disciplined capital allocation.
Follow ZBH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$88.29Current
$83Low
$118.98Average
$180High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 5, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Canaccord Genuity | Hold | Hold | Maintain | Aug 10, 2026 |
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 6, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Aug 6, 2026 |
| BMO Capital | Market Perform | Outperform | Downgrade | Jul 9, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Citigroup | Neutral | Neutral | Maintain | May 28, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Apr 29, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Apr 29, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Apr 29, 2026 |
| Barclays | Underweight | Underweight | Maintain | Apr 29, 2026 |
| BTIG | Neutral | Buy | Downgrade | Mar 23, 2026 |
| Needham | Hold | Hold | Maintain | Feb 10, 2026 |
| UBS | Sell | Sell | Maintain | Jan 28, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 8, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | May 7, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 6, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 6, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Oct 15, 2024 |
| TD Cowen | Hold | Hold | Maintain | Sep 6, 2024 |
| Piper Sandler | Neutral | Overweight | Downgrade | Jul 1, 2024 |
| Argus Research | Buy | Hold | Upgrade | May 21, 2024 |
| B of A Securities | Neutral | Underperform | Upgrade | May 3, 2023 |
| Jefferies | Hold | Underperform | Upgrade | Mar 31, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | May 4, 2022 |
| Loop Capital | Hold | Buy | Downgrade | Mar 2, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Feb 8, 2022 |
| Northland Capital Markets | Outperform | Market Perform | Upgrade | Apr 9, 2021 |
| Credit Suisse | Underperform | Underperform | Maintain | Nov 9, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 12, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Apr 28, 2020 |
| Argus | Buy | Hold | Upgrade | Aug 12, 2019 |
| Citi | Buy | Buy | Maintain | Aug 2, 2019 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 30, 2018 |
| Stifel Nicolaus | Buy | Hold | Upgrade | Jan 31, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Jan 31, 2018 |
| Edward Jones | Buy | Hold | Upgrade | Nov 9, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Nov 2, 2017 |
| Northcoast Research | Neutral | Buy | Downgrade | Nov 8, 2016 |
| Northland Securities | Perform | Outperform | Downgrade | Jan 7, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $88.29. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Canaccord Genuity | Caitlin Cronin | $100 | $96.55 | +13.3% | Aug 10, 2026 |
| Truist Financial | Analyst unavailable | $106 | $96.62 | +20.1% | Aug 6, 2026 |
| Robert W. Baird | Analyst unavailable | $104 | $97.32 | +17.8% | Aug 6, 2026 |
| UBS | Patrick Wood | $120 | $97.06 | +35.9% | Aug 6, 2026 |
| Bernstein | Analyst unavailable | $93 | $97.53 | +5.3% | Aug 6, 2026 |
| BMO Capital | Analyst unavailable | $96 | $98.16 | +8.7% | Aug 6, 2026 |
| RBC Capital | Kendall Au | $110 | $98.16 | +24.6% | Aug 6, 2026 |
| UBS | Patrick Wood | $115 | $92.07 | +30.3% | Jul 28, 2026 |
| BMO Capital | Analyst unavailable | $95 | $87.56 | +7.6% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $92 | $80.8 | +4.2% | Apr 29, 2026 |
| Canaccord Genuity | Analyst unavailable | $83 | $82.8 | -6.0% | Apr 29, 2026 |
| Stifel Nicolaus | Rick Wise | $105 | $82.8 | +18.9% | Apr 29, 2026 |
| Robert W. Baird | Analyst unavailable | $92 | $82.8 | +4.2% | Apr 29, 2026 |
| Barclays | Matt Miksic | $94 | $82.8 | +6.5% | Apr 29, 2026 |
| Barclays | Matt Miksic | $100 | $96.69 | +13.3% | Feb 12, 2026 |
| UBS | Analyst unavailable | $89 | $93.69 | +0.8% | Feb 11, 2026 |
| UBS | Analyst unavailable | $86 | $85.27 | -2.6% | Jan 28, 2026 |
| Bernstein | Analyst unavailable | $99 | $94.08 | +12.1% | Jan 9, 2026 |
| Goldman Sachs | David Roman | $93 | $94.08 | +5.3% | Jan 9, 2026 |
| Evercore ISI | Analyst unavailable | $120 | $90.02 | +35.9% | Jan 5, 2026 |
| Robert W. Baird | Jeff Johnson | $100 | $92.52 | +13.3% | Dec 16, 2025 |
| Stifel Nicolaus | Rick Wise | $110 | $87.91 | +24.6% | Nov 5, 2025 |
| Johnson Rice | Analyst unavailable | $112 | $88.05 | +26.9% | Nov 5, 2025 |
| Barclays | Analyst unavailable | $105 | $103.18 | +18.9% | Nov 5, 2025 |
| BTIG | Ryan Zimmerman | $122 | $94.71 | +38.2% | Oct 13, 2025 |
| RBC Capital | Analyst unavailable | $111 | $95.52 | +25.7% | Oct 10, 2025 |
| Stifel Nicolaus | Analyst unavailable | $118 | $100.36 | +33.7% | Sep 19, 2025 |
| Redburn Partners | Ed Ridley-Day | $130 | $100.21 | +47.2% | Sep 18, 2025 |
| UBS | Danielle Antalffy | $96 | $97.94 | +8.7% | Aug 8, 2025 |
| Truist Financial | Richard Newitter | $101 | $92.27 | +14.4% | May 6, 2025 |
| RBC Capital | Shagun Singh | $112 | $92.27 | +26.9% | May 6, 2025 |
| Stifel Nicolaus | Rick Wise | $115 | $90.48 | +30.3% | May 6, 2025 |
| Wells Fargo | Larry Biegelsen | $98 | $90.48 | +11.0% | May 5, 2025 |
| Truist Financial | Richard Newitter | $117 | $106.92 | +32.5% | Oct 31, 2024 |
| Oppenheimer | Steven Lichtman | $135 | $104.83 | +52.9% | Oct 15, 2024 |
| BTIG | Ryan Zimmerman | $126 | $105.69 | +42.7% | Oct 3, 2024 |
| Evercore ISI | Vijay Kumar | $110 | $107.95 | +24.6% | Oct 1, 2024 |
| Truist Financial | Richard Newitter | $112 | $105.14 | +26.9% | Sep 13, 2024 |
| Canaccord Genuity | Caitlin Cronin | $115 | $104.83 | +30.3% | Sep 10, 2024 |
| Raymond James | Jayson Bedford | $128 | $107.09 | +45.0% | Aug 8, 2024 |
| Oppenheimer | Steven Lichtman | $145 | $105.81 | +64.2% | Aug 8, 2024 |
| Stifel Nicolaus | Rick Wise | $130 | $107.5 | +47.2% | Aug 7, 2024 |
| Morgan Stanley | Drew Ranieri | $120 | $108.69 | +35.9% | Jul 15, 2024 |
| Piper Sandler | Matt O'Brien | $115 | $108.53 | +30.3% | Jul 1, 2024 |
| Piper Sandler | Matthew O\'Brien | $140 | $114.44 | +58.6% | May 31, 2024 |
| RBC Capital | Shagun Singh | $140 | $115.14 | +58.6% | May 30, 2024 |
| BTIG | Ryan Zimmerman | $139 | $116.41 | +57.4% | May 28, 2024 |
| Argus Research | David Toung | $150 | $119.05 | +69.9% | May 21, 2024 |
| Truist Financial | Analyst unavailable | $137 | $128.46 | +55.2% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $140 | $128.82 | +58.6% | Feb 6, 2023 |
| RBC Capital | Analyst unavailable | $141 | $125.7 | +59.7% | Jan 9, 2023 |
| Morgan Stanley | Analyst unavailable | $135 | $126.77 | +52.9% | Jan 6, 2023 |
| Truist Financial | Analyst unavailable | $135 | $124.91 | +52.9% | Dec 20, 2022 |
| Citigroup | Analyst unavailable | $130 | $125.36 | +47.2% | Dec 12, 2022 |
| Wells Fargo | Larry Biegelsen | $124 | $115.33 | +40.4% | Nov 23, 2022 |
| Stifel Nicolaus | Analyst unavailable | $120 | $104.62 | +35.9% | Jul 18, 2022 |
| RBC Capital | Analyst unavailable | $128 | $122.2 | +45.0% | May 4, 2022 |
| Piper Sandler | Matt O'Brien | $130 | $121.37 | +47.2% | May 3, 2022 |
| Bank of America Securities | Travis Steed | $120 | $122.13 | +35.9% | Mar 3, 2022 |
| JMP Securities | David Turkaly | $145 | $116.08 | +64.2% | Feb 8, 2022 |
| RBC Capital | Shagun Singh Chadha | $125 | $116.08 | +41.6% | Feb 8, 2022 |
| Truist Financial | Samuel Brodovsky | $128 | $116.08 | +45.0% | Feb 8, 2022 |
| Canaccord Genuity | Kyle Rose | $125 | $108.13 | +41.6% | Feb 7, 2022 |
| Deutsche Bank | Pito Chickering | $121 | $108.13 | +37.0% | Feb 7, 2022 |
| Leerink Partners | Danielle Antalffy | $135 | $108.13 | +52.9% | Feb 7, 2022 |
| Piper Sandler | Matthew O'Brien | $110 | $108.13 | +24.6% | Feb 7, 2022 |
| Robert W. Baird | Jeff Johnson | $138 | $108.13 | +56.3% | Feb 7, 2022 |
| Needham | Michael Matson | $143 | $108.13 | +62.0% | Feb 7, 2022 |
| Cowen & Co. | Josh Jennings | $140 | $119.14 | +58.6% | Jan 20, 2022 |
| Motley Fool | Anders Bylund | $140 | $121.23 | +58.6% | Dec 9, 2021 |
| Jefferies | Anthony Petrone | $175 | $136.9 | +98.2% | Nov 5, 2021 |
| Guggenheim | Christopher Pasquale | $180 | $136.9 | +103.9% | Nov 5, 2021 |
| Evercore ISI | Vijay Kumar | $170 | $133.13 | +92.5% | Nov 4, 2021 |
| Oppenheimer | Steven Lichtman | $190 | $143.03 | +115.2% | Aug 4, 2021 |
Track every rating change on ZBH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationZimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Historical context
All ZBH earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the ZBH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-05T02:40:43.669526+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-05T02:40:43.666888+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-05. For educational purposes only; not investment advice.